context stringlengths 21 33.9k | category stringclasses 2
values | entity stringlengths 1 12 | entity_type stringclasses 5
values | query stringlengths 97 3.31k | answer stringlengths 12 169 |
|---|---|---|---|---|---|
Common stock has been used from time to time to satisfy some of the funding requirements of employee and shareholder plans. During the years ended December 31, 2024, 2023, and 2022, we issued 5.4 million, 4.4 million and 2.1 million shares of common stock from treasury stock, which had aggregate values of $ 238 million, $ 192 million and $ 91 million, respectively. | text | 2.1 | sharesItemType | text: <entity> 2.1 </entity> <entity type> sharesItemType </entity type> <context> Common stock has been used from time to time to satisfy some of the funding requirements of employee and shareholder plans. During the years ended December 31, 2024, 2023, and 2022, we issued 5.4 million, 4.4 million and 2.1 million shares of common stock from treasury stock, which had aggregate values of $ 238 million, $ 192 million and $ 91 million, respectively. </context> | us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued |
Common stock has been used from time to time to satisfy some of the funding requirements of employee and shareholder plans. During the years ended December 31, 2024, 2023, and 2022, we issued 5.4 million, 4.4 million and 2.1 million shares of common stock from treasury stock, which had aggregate values of $ 238 million, $ 192 million and $ 91 million, respectively. | text | 238 | monetaryItemType | text: <entity> 238 </entity> <entity type> monetaryItemType </entity type> <context> Common stock has been used from time to time to satisfy some of the funding requirements of employee and shareholder plans. During the years ended December 31, 2024, 2023, and 2022, we issued 5.4 million, 4.4 million and 2.1 million shares of common stock from treasury stock, which had aggregate values of $ 238 million, $ 192 million and $ 91 million, respectively. </context> | us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued |
Common stock has been used from time to time to satisfy some of the funding requirements of employee and shareholder plans. During the years ended December 31, 2024, 2023, and 2022, we issued 5.4 million, 4.4 million and 2.1 million shares of common stock from treasury stock, which had aggregate values of $ 238 million, $ 192 million and $ 91 million, respectively. | text | 192 | monetaryItemType | text: <entity> 192 </entity> <entity type> monetaryItemType </entity type> <context> Common stock has been used from time to time to satisfy some of the funding requirements of employee and shareholder plans. During the years ended December 31, 2024, 2023, and 2022, we issued 5.4 million, 4.4 million and 2.1 million shares of common stock from treasury stock, which had aggregate values of $ 238 million, $ 192 million and $ 91 million, respectively. </context> | us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued |
Common stock has been used from time to time to satisfy some of the funding requirements of employee and shareholder plans. During the years ended December 31, 2024, 2023, and 2022, we issued 5.4 million, 4.4 million and 2.1 million shares of common stock from treasury stock, which had aggregate values of $ 238 million, $ 192 million and $ 91 million, respectively. | text | 91 | monetaryItemType | text: <entity> 91 </entity> <entity type> monetaryItemType </entity type> <context> Common stock has been used from time to time to satisfy some of the funding requirements of employee and shareholder plans. During the years ended December 31, 2024, 2023, and 2022, we issued 5.4 million, 4.4 million and 2.1 million shares of common stock from treasury stock, which had aggregate values of $ 238 million, $ 192 million and $ 91 million, respectively. </context> | us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued |
During the year ended December 31, 2024, Verizon entered into and completed agreements to acquire additional interests in certain controlled entities for cash consideration of $ 280 million. Verizon continues to retain controlling financial interest within these entities; therefore, the changes in ownership interest were accounted for as equity transactions. This resulted in a reduction of additional paid-in capital of $ 228 million, reflected in Other, and a reduction of noncontrolling interest of $ 52 million, | text | 280 | monetaryItemType | text: <entity> 280 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, Verizon entered into and completed agreements to acquire additional interests in certain controlled entities for cash consideration of $ 280 million. Verizon continues to retain controlling financial interest within these entities; therefore, the changes in ownership interest were accounted for as equity transactions. This resulted in a reduction of additional paid-in capital of $ 228 million, reflected in Other, and a reduction of noncontrolling interest of $ 52 million, </context> | us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries |
During the year ended December 31, 2024, Verizon entered into and completed agreements to acquire additional interests in certain controlled entities for cash consideration of $ 280 million. Verizon continues to retain controlling financial interest within these entities; therefore, the changes in ownership interest were accounted for as equity transactions. This resulted in a reduction of additional paid-in capital of $ 228 million, reflected in Other, and a reduction of noncontrolling interest of $ 52 million, | text | 228 | monetaryItemType | text: <entity> 228 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, Verizon entered into and completed agreements to acquire additional interests in certain controlled entities for cash consideration of $ 280 million. Verizon continues to retain controlling financial interest within these entities; therefore, the changes in ownership interest were accounted for as equity transactions. This resulted in a reduction of additional paid-in capital of $ 228 million, reflected in Other, and a reduction of noncontrolling interest of $ 52 million, </context> | us-gaap:AdjustmentsToAdditionalPaidInCapitalOther |
During the year ended December 31, 2024, Verizon entered into and completed agreements to acquire additional interests in certain controlled entities for cash consideration of $ 280 million. Verizon continues to retain controlling financial interest within these entities; therefore, the changes in ownership interest were accounted for as equity transactions. This resulted in a reduction of additional paid-in capital of $ 228 million, reflected in Other, and a reduction of noncontrolling interest of $ 52 million, | text | 52 | monetaryItemType | text: <entity> 52 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, Verizon entered into and completed agreements to acquire additional interests in certain controlled entities for cash consideration of $ 280 million. Verizon continues to retain controlling financial interest within these entities; therefore, the changes in ownership interest were accounted for as equity transactions. This resulted in a reduction of additional paid-in capital of $ 228 million, reflected in Other, and a reduction of noncontrolling interest of $ 52 million, </context> | us-gaap:MinorityInterestDecreaseFromRedemptions |
As of December 31, 2024 and 2023, Property, plant and equipment includes approximately $ 3.3 billion and $ 3.8 billion, respectively, of additions that have not yet been paid. | text | 3.3 | monetaryItemType | text: <entity> 3.3 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, Property, plant and equipment includes approximately $ 3.3 billion and $ 3.8 billion, respectively, of additions that have not yet been paid. </context> | us-gaap:CapitalExpendituresIncurredButNotYetPaid |
As of December 31, 2024 and 2023, Property, plant and equipment includes approximately $ 3.3 billion and $ 3.8 billion, respectively, of additions that have not yet been paid. | text | 3.8 | monetaryItemType | text: <entity> 3.8 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, Property, plant and equipment includes approximately $ 3.3 billion and $ 3.8 billion, respectively, of additions that have not yet been paid. </context> | us-gaap:CapitalExpendituresIncurredButNotYetPaid |
As of December 31, 2024, letters of credit totaling approximately $ 816 million, which were executed in the normal course of business and support several financing arrangements and payment obligations to third parties, were outstanding. | text | 816 | monetaryItemType | text: <entity> 816 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, letters of credit totaling approximately $ 816 million, which were executed in the normal course of business and support several financing arrangements and payment obligations to third parties, were outstanding. </context> | us-gaap:LettersOfCreditOutstandingAmount |
We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms in excess of one year, total $ 16.7 billion, and primarily represent commitments to purchase content, network equipment, software and services, marketing services and other items which will be used or sold in the ordinary course of business from a variety of suppliers. Of this total amount, $ 6.2 billion is attributable to 2025, $ 5.5 billion is attributable to 2026, $ 3.1 billion is attributable to 2027, $ 1.3 billion is attributable to 2028, $ 291 million is attributable to 2029 and $ 363 million is attributable to years thereafter. These amounts do not represent our entire anticipated purchases in the future, but represent only those items that are the subject of contractual obligations. Our commitments are generally determined based on the noncancelable quantities to which we are contractually obliged. Since the commitments to purchase programming services from television networks and broadcast stations have no minimum volume requirement, we estimated our obligation based on number of subscribers at December 31, 2024, and applicable rates stipulated in the contracts in effect at that time. We also purchase products and services as needed with no firm commitment. | text | 16.7 | monetaryItemType | text: <entity> 16.7 </entity> <entity type> monetaryItemType </entity type> <context> We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms in excess of one year, total $ 16.7 billion, and primarily represent commitments to purchase content, network equipment, software and services, marketing services and other items which will be used or sold in the ordinary course of business from a variety of suppliers. Of this total amount, $ 6.2 billion is attributable to 2025, $ 5.5 billion is attributable to 2026, $ 3.1 billion is attributable to 2027, $ 1.3 billion is attributable to 2028, $ 291 million is attributable to 2029 and $ 363 million is attributable to years thereafter. These amounts do not represent our entire anticipated purchases in the future, but represent only those items that are the subject of contractual obligations. Our commitments are generally determined based on the noncancelable quantities to which we are contractually obliged. Since the commitments to purchase programming services from television networks and broadcast stations have no minimum volume requirement, we estimated our obligation based on number of subscribers at December 31, 2024, and applicable rates stipulated in the contracts in effect at that time. We also purchase products and services as needed with no firm commitment. </context> | us-gaap:RecordedUnconditionalPurchaseObligation |
We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms in excess of one year, total $ 16.7 billion, and primarily represent commitments to purchase content, network equipment, software and services, marketing services and other items which will be used or sold in the ordinary course of business from a variety of suppliers. Of this total amount, $ 6.2 billion is attributable to 2025, $ 5.5 billion is attributable to 2026, $ 3.1 billion is attributable to 2027, $ 1.3 billion is attributable to 2028, $ 291 million is attributable to 2029 and $ 363 million is attributable to years thereafter. These amounts do not represent our entire anticipated purchases in the future, but represent only those items that are the subject of contractual obligations. Our commitments are generally determined based on the noncancelable quantities to which we are contractually obliged. Since the commitments to purchase programming services from television networks and broadcast stations have no minimum volume requirement, we estimated our obligation based on number of subscribers at December 31, 2024, and applicable rates stipulated in the contracts in effect at that time. We also purchase products and services as needed with no firm commitment. | text | 6.2 | monetaryItemType | text: <entity> 6.2 </entity> <entity type> monetaryItemType </entity type> <context> We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms in excess of one year, total $ 16.7 billion, and primarily represent commitments to purchase content, network equipment, software and services, marketing services and other items which will be used or sold in the ordinary course of business from a variety of suppliers. Of this total amount, $ 6.2 billion is attributable to 2025, $ 5.5 billion is attributable to 2026, $ 3.1 billion is attributable to 2027, $ 1.3 billion is attributable to 2028, $ 291 million is attributable to 2029 and $ 363 million is attributable to years thereafter. These amounts do not represent our entire anticipated purchases in the future, but represent only those items that are the subject of contractual obligations. Our commitments are generally determined based on the noncancelable quantities to which we are contractually obliged. Since the commitments to purchase programming services from television networks and broadcast stations have no minimum volume requirement, we estimated our obligation based on number of subscribers at December 31, 2024, and applicable rates stipulated in the contracts in effect at that time. We also purchase products and services as needed with no firm commitment. </context> | us-gaap:RecordedUnconditionalPurchaseObligationDueWithinOneYear |
We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms in excess of one year, total $ 16.7 billion, and primarily represent commitments to purchase content, network equipment, software and services, marketing services and other items which will be used or sold in the ordinary course of business from a variety of suppliers. Of this total amount, $ 6.2 billion is attributable to 2025, $ 5.5 billion is attributable to 2026, $ 3.1 billion is attributable to 2027, $ 1.3 billion is attributable to 2028, $ 291 million is attributable to 2029 and $ 363 million is attributable to years thereafter. These amounts do not represent our entire anticipated purchases in the future, but represent only those items that are the subject of contractual obligations. Our commitments are generally determined based on the noncancelable quantities to which we are contractually obliged. Since the commitments to purchase programming services from television networks and broadcast stations have no minimum volume requirement, we estimated our obligation based on number of subscribers at December 31, 2024, and applicable rates stipulated in the contracts in effect at that time. We also purchase products and services as needed with no firm commitment. | text | 5.5 | monetaryItemType | text: <entity> 5.5 </entity> <entity type> monetaryItemType </entity type> <context> We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms in excess of one year, total $ 16.7 billion, and primarily represent commitments to purchase content, network equipment, software and services, marketing services and other items which will be used or sold in the ordinary course of business from a variety of suppliers. Of this total amount, $ 6.2 billion is attributable to 2025, $ 5.5 billion is attributable to 2026, $ 3.1 billion is attributable to 2027, $ 1.3 billion is attributable to 2028, $ 291 million is attributable to 2029 and $ 363 million is attributable to years thereafter. These amounts do not represent our entire anticipated purchases in the future, but represent only those items that are the subject of contractual obligations. Our commitments are generally determined based on the noncancelable quantities to which we are contractually obliged. Since the commitments to purchase programming services from television networks and broadcast stations have no minimum volume requirement, we estimated our obligation based on number of subscribers at December 31, 2024, and applicable rates stipulated in the contracts in effect at that time. We also purchase products and services as needed with no firm commitment. </context> | us-gaap:RecordedUnconditionalPurchaseObligationDueInSecondYear |
We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms in excess of one year, total $ 16.7 billion, and primarily represent commitments to purchase content, network equipment, software and services, marketing services and other items which will be used or sold in the ordinary course of business from a variety of suppliers. Of this total amount, $ 6.2 billion is attributable to 2025, $ 5.5 billion is attributable to 2026, $ 3.1 billion is attributable to 2027, $ 1.3 billion is attributable to 2028, $ 291 million is attributable to 2029 and $ 363 million is attributable to years thereafter. These amounts do not represent our entire anticipated purchases in the future, but represent only those items that are the subject of contractual obligations. Our commitments are generally determined based on the noncancelable quantities to which we are contractually obliged. Since the commitments to purchase programming services from television networks and broadcast stations have no minimum volume requirement, we estimated our obligation based on number of subscribers at December 31, 2024, and applicable rates stipulated in the contracts in effect at that time. We also purchase products and services as needed with no firm commitment. | text | 3.1 | monetaryItemType | text: <entity> 3.1 </entity> <entity type> monetaryItemType </entity type> <context> We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms in excess of one year, total $ 16.7 billion, and primarily represent commitments to purchase content, network equipment, software and services, marketing services and other items which will be used or sold in the ordinary course of business from a variety of suppliers. Of this total amount, $ 6.2 billion is attributable to 2025, $ 5.5 billion is attributable to 2026, $ 3.1 billion is attributable to 2027, $ 1.3 billion is attributable to 2028, $ 291 million is attributable to 2029 and $ 363 million is attributable to years thereafter. These amounts do not represent our entire anticipated purchases in the future, but represent only those items that are the subject of contractual obligations. Our commitments are generally determined based on the noncancelable quantities to which we are contractually obliged. Since the commitments to purchase programming services from television networks and broadcast stations have no minimum volume requirement, we estimated our obligation based on number of subscribers at December 31, 2024, and applicable rates stipulated in the contracts in effect at that time. We also purchase products and services as needed with no firm commitment. </context> | us-gaap:RecordedUnconditionalPurchaseObligationDueInThirdYear |
We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms in excess of one year, total $ 16.7 billion, and primarily represent commitments to purchase content, network equipment, software and services, marketing services and other items which will be used or sold in the ordinary course of business from a variety of suppliers. Of this total amount, $ 6.2 billion is attributable to 2025, $ 5.5 billion is attributable to 2026, $ 3.1 billion is attributable to 2027, $ 1.3 billion is attributable to 2028, $ 291 million is attributable to 2029 and $ 363 million is attributable to years thereafter. These amounts do not represent our entire anticipated purchases in the future, but represent only those items that are the subject of contractual obligations. Our commitments are generally determined based on the noncancelable quantities to which we are contractually obliged. Since the commitments to purchase programming services from television networks and broadcast stations have no minimum volume requirement, we estimated our obligation based on number of subscribers at December 31, 2024, and applicable rates stipulated in the contracts in effect at that time. We also purchase products and services as needed with no firm commitment. | text | 1.3 | monetaryItemType | text: <entity> 1.3 </entity> <entity type> monetaryItemType </entity type> <context> We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms in excess of one year, total $ 16.7 billion, and primarily represent commitments to purchase content, network equipment, software and services, marketing services and other items which will be used or sold in the ordinary course of business from a variety of suppliers. Of this total amount, $ 6.2 billion is attributable to 2025, $ 5.5 billion is attributable to 2026, $ 3.1 billion is attributable to 2027, $ 1.3 billion is attributable to 2028, $ 291 million is attributable to 2029 and $ 363 million is attributable to years thereafter. These amounts do not represent our entire anticipated purchases in the future, but represent only those items that are the subject of contractual obligations. Our commitments are generally determined based on the noncancelable quantities to which we are contractually obliged. Since the commitments to purchase programming services from television networks and broadcast stations have no minimum volume requirement, we estimated our obligation based on number of subscribers at December 31, 2024, and applicable rates stipulated in the contracts in effect at that time. We also purchase products and services as needed with no firm commitment. </context> | us-gaap:RecordedUnconditionalPurchaseObligationDueInFourthYear |
We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms in excess of one year, total $ 16.7 billion, and primarily represent commitments to purchase content, network equipment, software and services, marketing services and other items which will be used or sold in the ordinary course of business from a variety of suppliers. Of this total amount, $ 6.2 billion is attributable to 2025, $ 5.5 billion is attributable to 2026, $ 3.1 billion is attributable to 2027, $ 1.3 billion is attributable to 2028, $ 291 million is attributable to 2029 and $ 363 million is attributable to years thereafter. These amounts do not represent our entire anticipated purchases in the future, but represent only those items that are the subject of contractual obligations. Our commitments are generally determined based on the noncancelable quantities to which we are contractually obliged. Since the commitments to purchase programming services from television networks and broadcast stations have no minimum volume requirement, we estimated our obligation based on number of subscribers at December 31, 2024, and applicable rates stipulated in the contracts in effect at that time. We also purchase products and services as needed with no firm commitment. | text | 291 | monetaryItemType | text: <entity> 291 </entity> <entity type> monetaryItemType </entity type> <context> We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms in excess of one year, total $ 16.7 billion, and primarily represent commitments to purchase content, network equipment, software and services, marketing services and other items which will be used or sold in the ordinary course of business from a variety of suppliers. Of this total amount, $ 6.2 billion is attributable to 2025, $ 5.5 billion is attributable to 2026, $ 3.1 billion is attributable to 2027, $ 1.3 billion is attributable to 2028, $ 291 million is attributable to 2029 and $ 363 million is attributable to years thereafter. These amounts do not represent our entire anticipated purchases in the future, but represent only those items that are the subject of contractual obligations. Our commitments are generally determined based on the noncancelable quantities to which we are contractually obliged. Since the commitments to purchase programming services from television networks and broadcast stations have no minimum volume requirement, we estimated our obligation based on number of subscribers at December 31, 2024, and applicable rates stipulated in the contracts in effect at that time. We also purchase products and services as needed with no firm commitment. </context> | us-gaap:RecordedUnconditionalPurchaseObligationDueInFifthYear |
We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms in excess of one year, total $ 16.7 billion, and primarily represent commitments to purchase content, network equipment, software and services, marketing services and other items which will be used or sold in the ordinary course of business from a variety of suppliers. Of this total amount, $ 6.2 billion is attributable to 2025, $ 5.5 billion is attributable to 2026, $ 3.1 billion is attributable to 2027, $ 1.3 billion is attributable to 2028, $ 291 million is attributable to 2029 and $ 363 million is attributable to years thereafter. These amounts do not represent our entire anticipated purchases in the future, but represent only those items that are the subject of contractual obligations. Our commitments are generally determined based on the noncancelable quantities to which we are contractually obliged. Since the commitments to purchase programming services from television networks and broadcast stations have no minimum volume requirement, we estimated our obligation based on number of subscribers at December 31, 2024, and applicable rates stipulated in the contracts in effect at that time. We also purchase products and services as needed with no firm commitment. | text | 363 | monetaryItemType | text: <entity> 363 </entity> <entity type> monetaryItemType </entity type> <context> We have various unconditional purchase obligations, which represent agreements to purchase goods or services that are enforceable and legally binding. We estimate that these unconditional purchase obligations, for contracts with terms in excess of one year, total $ 16.7 billion, and primarily represent commitments to purchase content, network equipment, software and services, marketing services and other items which will be used or sold in the ordinary course of business from a variety of suppliers. Of this total amount, $ 6.2 billion is attributable to 2025, $ 5.5 billion is attributable to 2026, $ 3.1 billion is attributable to 2027, $ 1.3 billion is attributable to 2028, $ 291 million is attributable to 2029 and $ 363 million is attributable to years thereafter. These amounts do not represent our entire anticipated purchases in the future, but represent only those items that are the subject of contractual obligations. Our commitments are generally determined based on the noncancelable quantities to which we are contractually obliged. Since the commitments to purchase programming services from television networks and broadcast stations have no minimum volume requirement, we estimated our obligation based on number of subscribers at December 31, 2024, and applicable rates stipulated in the contracts in effect at that time. We also purchase products and services as needed with no firm commitment. </context> | us-gaap:RecordedUnconditionalPurchaseObligationDueAfterFifthYear |
Allowance for credit losses includes approximately $ 617 million, $ 592 million, and $ 436 million at December 31, 2024, 2023, and 2022, respectively, related to long-term device payment receivables. | text | 617 | monetaryItemType | text: <entity> 617 </entity> <entity type> monetaryItemType </entity type> <context> Allowance for credit losses includes approximately $ 617 million, $ 592 million, and $ 436 million at December 31, 2024, 2023, and 2022, respectively, related to long-term device payment receivables. </context> | us-gaap:ValuationAllowancesAndReservesBalance |
Allowance for credit losses includes approximately $ 617 million, $ 592 million, and $ 436 million at December 31, 2024, 2023, and 2022, respectively, related to long-term device payment receivables. | text | 592 | monetaryItemType | text: <entity> 592 </entity> <entity type> monetaryItemType </entity type> <context> Allowance for credit losses includes approximately $ 617 million, $ 592 million, and $ 436 million at December 31, 2024, 2023, and 2022, respectively, related to long-term device payment receivables. </context> | us-gaap:ValuationAllowancesAndReservesBalance |
Allowance for credit losses includes approximately $ 617 million, $ 592 million, and $ 436 million at December 31, 2024, 2023, and 2022, respectively, related to long-term device payment receivables. | text | 436 | monetaryItemType | text: <entity> 436 </entity> <entity type> monetaryItemType </entity type> <context> Allowance for credit losses includes approximately $ 617 million, $ 592 million, and $ 436 million at December 31, 2024, 2023, and 2022, respectively, related to long-term device payment receivables. </context> | us-gaap:ValuationAllowancesAndReservesBalance |
Advertising and product promotion costs are expensed as incurred. Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $ 1.5 billion in 2024, $ 1.4 billion in 2023 and $ 1.3 billion in 2022. | text | 1.5 | monetaryItemType | text: <entity> 1.5 </entity> <entity type> monetaryItemType </entity type> <context> Advertising and product promotion costs are expensed as incurred. Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $ 1.5 billion in 2024, $ 1.4 billion in 2023 and $ 1.3 billion in 2022. </context> | us-gaap:MarketingAndAdvertisingExpense |
Advertising and product promotion costs are expensed as incurred. Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $ 1.5 billion in 2024, $ 1.4 billion in 2023 and $ 1.3 billion in 2022. | text | 1.4 | monetaryItemType | text: <entity> 1.4 </entity> <entity type> monetaryItemType </entity type> <context> Advertising and product promotion costs are expensed as incurred. Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $ 1.5 billion in 2024, $ 1.4 billion in 2023 and $ 1.3 billion in 2022. </context> | us-gaap:MarketingAndAdvertisingExpense |
Advertising and product promotion costs are expensed as incurred. Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $ 1.5 billion in 2024, $ 1.4 billion in 2023 and $ 1.3 billion in 2022. | text | 1.3 | monetaryItemType | text: <entity> 1.3 </entity> <entity type> monetaryItemType </entity type> <context> Advertising and product promotion costs are expensed as incurred. Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were $ 1.5 billion in 2024, $ 1.4 billion in 2023 and $ 1.3 billion in 2022. </context> | us-gaap:MarketingAndAdvertisingExpense |
Contract assets are primarily estimated future royalties and termination fees not eligible for the licensing exclusion and therefore recognized under ASC 606 and ASC 610. Contract assets are reduced and receivables are increased in the period the underlying sales occur. Cumulative catch-up adjustments to revenue affecting contract assets or contract liabilities were not material in 2024, 2023 and 2022. Revenue recognized from performance obligations satisfied in prior periods was $ 797 million in 2024, $ 462 million in 2023, and $ 556 million in 2022 consisting primarily of revised estimates for GTN adjustments related to prior period sales and royalties from out-licensing arrangements. | text | 797 | monetaryItemType | text: <entity> 797 </entity> <entity type> monetaryItemType </entity type> <context> Contract assets are primarily estimated future royalties and termination fees not eligible for the licensing exclusion and therefore recognized under ASC 606 and ASC 610. Contract assets are reduced and receivables are increased in the period the underlying sales occur. Cumulative catch-up adjustments to revenue affecting contract assets or contract liabilities were not material in 2024, 2023 and 2022. Revenue recognized from performance obligations satisfied in prior periods was $ 797 million in 2024, $ 462 million in 2023, and $ 556 million in 2022 consisting primarily of revised estimates for GTN adjustments related to prior period sales and royalties from out-licensing arrangements. </context> | us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod |
Contract assets are primarily estimated future royalties and termination fees not eligible for the licensing exclusion and therefore recognized under ASC 606 and ASC 610. Contract assets are reduced and receivables are increased in the period the underlying sales occur. Cumulative catch-up adjustments to revenue affecting contract assets or contract liabilities were not material in 2024, 2023 and 2022. Revenue recognized from performance obligations satisfied in prior periods was $ 797 million in 2024, $ 462 million in 2023, and $ 556 million in 2022 consisting primarily of revised estimates for GTN adjustments related to prior period sales and royalties from out-licensing arrangements. | text | 462 | monetaryItemType | text: <entity> 462 </entity> <entity type> monetaryItemType </entity type> <context> Contract assets are primarily estimated future royalties and termination fees not eligible for the licensing exclusion and therefore recognized under ASC 606 and ASC 610. Contract assets are reduced and receivables are increased in the period the underlying sales occur. Cumulative catch-up adjustments to revenue affecting contract assets or contract liabilities were not material in 2024, 2023 and 2022. Revenue recognized from performance obligations satisfied in prior periods was $ 797 million in 2024, $ 462 million in 2023, and $ 556 million in 2022 consisting primarily of revised estimates for GTN adjustments related to prior period sales and royalties from out-licensing arrangements. </context> | us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod |
Contract assets are primarily estimated future royalties and termination fees not eligible for the licensing exclusion and therefore recognized under ASC 606 and ASC 610. Contract assets are reduced and receivables are increased in the period the underlying sales occur. Cumulative catch-up adjustments to revenue affecting contract assets or contract liabilities were not material in 2024, 2023 and 2022. Revenue recognized from performance obligations satisfied in prior periods was $ 797 million in 2024, $ 462 million in 2023, and $ 556 million in 2022 consisting primarily of revised estimates for GTN adjustments related to prior period sales and royalties from out-licensing arrangements. | text | 556 | monetaryItemType | text: <entity> 556 </entity> <entity type> monetaryItemType </entity type> <context> Contract assets are primarily estimated future royalties and termination fees not eligible for the licensing exclusion and therefore recognized under ASC 606 and ASC 610. Contract assets are reduced and receivables are increased in the period the underlying sales occur. Cumulative catch-up adjustments to revenue affecting contract assets or contract liabilities were not material in 2024, 2023 and 2022. Revenue recognized from performance obligations satisfied in prior periods was $ 797 million in 2024, $ 462 million in 2023, and $ 556 million in 2022 consisting primarily of revised estimates for GTN adjustments related to prior period sales and royalties from out-licensing arrangements. </context> | us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod |
in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. | text | 242 | monetaryItemType | text: <entity> 242 </entity> <entity type> monetaryItemType </entity type> <context> in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. </context> | us-gaap:Revenues |
in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. | text | 358 | monetaryItemType | text: <entity> 358 </entity> <entity type> monetaryItemType </entity type> <context> in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. </context> | us-gaap:Revenues |
in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. | text | 297 | monetaryItemType | text: <entity> 297 </entity> <entity type> monetaryItemType </entity type> <context> in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. </context> | us-gaap:Revenues |
in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. | text | 43 | monetaryItemType | text: <entity> 43 </entity> <entity type> monetaryItemType </entity type> <context> in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. </context> | us-gaap:CostOfGoodsAndServicesSold |
in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. | text | 109 | monetaryItemType | text: <entity> 109 </entity> <entity type> monetaryItemType </entity type> <context> in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. </context> | us-gaap:CostOfGoodsAndServicesSold |
in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. | text | 49 | monetaryItemType | text: <entity> 49 </entity> <entity type> monetaryItemType </entity type> <context> in the U.S. were $ 242 million, $ 358 million and $ 297 million; and the related profit sharing costs were $ 43 million, $ 109 million and $ 49 million in 2024, 2023 and 2022, respectively. Cost reimbursements were not material. </context> | us-gaap:CostOfGoodsAndServicesSold |
BMS acquired all of the issued and outstanding shares of RayzeBio's common stock for $ 62.50 per share in an all-cash transaction for total consideration of $ 4.1 billion, or $ 3.6 billion net of cash acquired. The acquisition was funded through a combination of cash on hand and debt proceeds (see "—Note 10. Financing Arrangements" for further detail). | text | 62.50 | perShareItemType | text: <entity> 62.50 </entity> <entity type> perShareItemType </entity type> <context> BMS acquired all of the issued and outstanding shares of RayzeBio's common stock for $ 62.50 per share in an all-cash transaction for total consideration of $ 4.1 billion, or $ 3.6 billion net of cash acquired. The acquisition was funded through a combination of cash on hand and debt proceeds (see "—Note 10. Financing Arrangements" for further detail). </context> | us-gaap:BusinessAcquisitionSharePrice |
BMS acquired all of the issued and outstanding shares of RayzeBio's common stock for $ 62.50 per share in an all-cash transaction for total consideration of $ 4.1 billion, or $ 3.6 billion net of cash acquired. The acquisition was funded through a combination of cash on hand and debt proceeds (see "—Note 10. Financing Arrangements" for further detail). | text | 4.1 | monetaryItemType | text: <entity> 4.1 </entity> <entity type> monetaryItemType </entity type> <context> BMS acquired all of the issued and outstanding shares of RayzeBio's common stock for $ 62.50 per share in an all-cash transaction for total consideration of $ 4.1 billion, or $ 3.6 billion net of cash acquired. The acquisition was funded through a combination of cash on hand and debt proceeds (see "—Note 10. Financing Arrangements" for further detail). </context> | us-gaap:PaymentsToAcquireBusinessesGross |
BMS acquired all of the issued and outstanding shares of RayzeBio's common stock for $ 62.50 per share in an all-cash transaction for total consideration of $ 4.1 billion, or $ 3.6 billion net of cash acquired. The acquisition was funded through a combination of cash on hand and debt proceeds (see "—Note 10. Financing Arrangements" for further detail). | text | 3.6 | monetaryItemType | text: <entity> 3.6 </entity> <entity type> monetaryItemType </entity type> <context> BMS acquired all of the issued and outstanding shares of RayzeBio's common stock for $ 62.50 per share in an all-cash transaction for total consideration of $ 4.1 billion, or $ 3.6 billion net of cash acquired. The acquisition was funded through a combination of cash on hand and debt proceeds (see "—Note 10. Financing Arrangements" for further detail). </context> | us-gaap:BusinessCombinationConsiderationTransferred1 |
(a) Includes cash settlement for unvested equity awards of $ 159 million expensed in Marketing, selling and administrative and $ 115 million expensed in Research and development during the twelve months ended December 31, 2024. | text | 159 | monetaryItemType | text: <entity> 159 </entity> <entity type> monetaryItemType </entity type> <context> (a) Includes cash settlement for unvested equity awards of $ 159 million expensed in Marketing, selling and administrative and $ 115 million expensed in Research and development during the twelve months ended December 31, 2024. </context> | us-gaap:PaymentsToAcquireBusinessesGross |
(a) Includes cash settlement for unvested equity awards of $ 159 million expensed in Marketing, selling and administrative and $ 115 million expensed in Research and development during the twelve months ended December 31, 2024. | text | 115 | monetaryItemType | text: <entity> 115 </entity> <entity type> monetaryItemType </entity type> <context> (a) Includes cash settlement for unvested equity awards of $ 159 million expensed in Marketing, selling and administrative and $ 115 million expensed in Research and development during the twelve months ended December 31, 2024. </context> | us-gaap:PaymentsToAcquireBusinessesGross |
Intangible assets included $ 1.7 billion of indefinite-lived IPRD and $ 2.0 billion of R&D technology. The estimated fair values for the indefinite-lived IPRD asset and the R&D technology were determined using an income approach valuation method. Goodwill resulted primarily from the recognition of deferred tax liabilities and is not deductible for tax purposes. | text | 1.7 | monetaryItemType | text: <entity> 1.7 </entity> <entity type> monetaryItemType </entity type> <context> Intangible assets included $ 1.7 billion of indefinite-lived IPRD and $ 2.0 billion of R&D technology. The estimated fair values for the indefinite-lived IPRD asset and the R&D technology were determined using an income approach valuation method. Goodwill resulted primarily from the recognition of deferred tax liabilities and is not deductible for tax purposes. </context> | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets |
Intangible assets included $ 1.7 billion of indefinite-lived IPRD and $ 2.0 billion of R&D technology. The estimated fair values for the indefinite-lived IPRD asset and the R&D technology were determined using an income approach valuation method. Goodwill resulted primarily from the recognition of deferred tax liabilities and is not deductible for tax purposes. | text | 2.0 | monetaryItemType | text: <entity> 2.0 </entity> <entity type> monetaryItemType </entity type> <context> Intangible assets included $ 1.7 billion of indefinite-lived IPRD and $ 2.0 billion of R&D technology. The estimated fair values for the indefinite-lived IPRD asset and the R&D technology were determined using an income approach valuation method. Goodwill resulted primarily from the recognition of deferred tax liabilities and is not deductible for tax purposes. </context> | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets |
BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of cash acquired. Mirati stockholders also received one non-tradeable contingent value right (CVR) for each share of Mirati common stock held, potentially worth $ 12.00 per share in cash for a total value of approximately $ 1.0 billion. The payout of the contingent value right is subject to the FDA acceptance of an NDA for PRMT5 Inhibitor for the treatment of specific indications within seven years of the closing of the transaction. The acquisition was funded through a combination of cash on hand and debt proceeds (see "—Note 10. Financing Arrangements" for further detail). | text | 58.00 | perShareItemType | text: <entity> 58.00 </entity> <entity type> perShareItemType </entity type> <context> BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of cash acquired. Mirati stockholders also received one non-tradeable contingent value right (CVR) for each share of Mirati common stock held, potentially worth $ 12.00 per share in cash for a total value of approximately $ 1.0 billion. The payout of the contingent value right is subject to the FDA acceptance of an NDA for PRMT5 Inhibitor for the treatment of specific indications within seven years of the closing of the transaction. The acquisition was funded through a combination of cash on hand and debt proceeds (see "—Note 10. Financing Arrangements" for further detail). </context> | us-gaap:BusinessAcquisitionSharePrice |
BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of cash acquired. Mirati stockholders also received one non-tradeable contingent value right (CVR) for each share of Mirati common stock held, potentially worth $ 12.00 per share in cash for a total value of approximately $ 1.0 billion. The payout of the contingent value right is subject to the FDA acceptance of an NDA for PRMT5 Inhibitor for the treatment of specific indications within seven years of the closing of the transaction. The acquisition was funded through a combination of cash on hand and debt proceeds (see "—Note 10. Financing Arrangements" for further detail). | text | 4.8 | monetaryItemType | text: <entity> 4.8 </entity> <entity type> monetaryItemType </entity type> <context> BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of cash acquired. Mirati stockholders also received one non-tradeable contingent value right (CVR) for each share of Mirati common stock held, potentially worth $ 12.00 per share in cash for a total value of approximately $ 1.0 billion. The payout of the contingent value right is subject to the FDA acceptance of an NDA for PRMT5 Inhibitor for the treatment of specific indications within seven years of the closing of the transaction. The acquisition was funded through a combination of cash on hand and debt proceeds (see "—Note 10. Financing Arrangements" for further detail). </context> | us-gaap:PaymentsToAcquireBusinessesGross |
BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of cash acquired. Mirati stockholders also received one non-tradeable contingent value right (CVR) for each share of Mirati common stock held, potentially worth $ 12.00 per share in cash for a total value of approximately $ 1.0 billion. The payout of the contingent value right is subject to the FDA acceptance of an NDA for PRMT5 Inhibitor for the treatment of specific indications within seven years of the closing of the transaction. The acquisition was funded through a combination of cash on hand and debt proceeds (see "—Note 10. Financing Arrangements" for further detail). | text | 4.1 | monetaryItemType | text: <entity> 4.1 </entity> <entity type> monetaryItemType </entity type> <context> BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of cash acquired. Mirati stockholders also received one non-tradeable contingent value right (CVR) for each share of Mirati common stock held, potentially worth $ 12.00 per share in cash for a total value of approximately $ 1.0 billion. The payout of the contingent value right is subject to the FDA acceptance of an NDA for PRMT5 Inhibitor for the treatment of specific indications within seven years of the closing of the transaction. The acquisition was funded through a combination of cash on hand and debt proceeds (see "—Note 10. Financing Arrangements" for further detail). </context> | us-gaap:BusinessCombinationConsiderationTransferred1 |
BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of cash acquired. Mirati stockholders also received one non-tradeable contingent value right (CVR) for each share of Mirati common stock held, potentially worth $ 12.00 per share in cash for a total value of approximately $ 1.0 billion. The payout of the contingent value right is subject to the FDA acceptance of an NDA for PRMT5 Inhibitor for the treatment of specific indications within seven years of the closing of the transaction. The acquisition was funded through a combination of cash on hand and debt proceeds (see "—Note 10. Financing Arrangements" for further detail). | text | 1.0 | monetaryItemType | text: <entity> 1.0 </entity> <entity type> monetaryItemType </entity type> <context> BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of cash acquired. Mirati stockholders also received one non-tradeable contingent value right (CVR) for each share of Mirati common stock held, potentially worth $ 12.00 per share in cash for a total value of approximately $ 1.0 billion. The payout of the contingent value right is subject to the FDA acceptance of an NDA for PRMT5 Inhibitor for the treatment of specific indications within seven years of the closing of the transaction. The acquisition was funded through a combination of cash on hand and debt proceeds (see "—Note 10. Financing Arrangements" for further detail). </context> | us-gaap:BusinessCombinationContingentConsiderationLiability |
(a) Includes cash settlement of unvested equity awards of $ 60 million expensed in Marketing, selling and administrative and $ 54 million expensed in Research and development during twelve months ended December 31, 2024. | text | 60 | monetaryItemType | text: <entity> 60 </entity> <entity type> monetaryItemType </entity type> <context> (a) Includes cash settlement of unvested equity awards of $ 60 million expensed in Marketing, selling and administrative and $ 54 million expensed in Research and development during twelve months ended December 31, 2024. </context> | us-gaap:PaymentsToAcquireBusinessesGross |
(a) Includes cash settlement of unvested equity awards of $ 60 million expensed in Marketing, selling and administrative and $ 54 million expensed in Research and development during twelve months ended December 31, 2024. | text | 54 | monetaryItemType | text: <entity> 54 </entity> <entity type> monetaryItemType </entity type> <context> (a) Includes cash settlement of unvested equity awards of $ 60 million expensed in Marketing, selling and administrative and $ 54 million expensed in Research and development during twelve months ended December 31, 2024. </context> | us-gaap:PaymentsToAcquireBusinessesGross |
Inventories includes a fair value adjustment of $ 148 million. Intangible assets included $ 640 million of definite-lived Acquired marketed product rights ( | text | 148 | monetaryItemType | text: <entity> 148 </entity> <entity type> monetaryItemType </entity type> <context> Inventories includes a fair value adjustment of $ 148 million. Intangible assets included $ 640 million of definite-lived Acquired marketed product rights ( </context> | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory |
Inventories includes a fair value adjustment of $ 148 million. Intangible assets included $ 640 million of definite-lived Acquired marketed product rights ( | text | 640 | monetaryItemType | text: <entity> 640 </entity> <entity type> monetaryItemType </entity type> <context> Inventories includes a fair value adjustment of $ 148 million. Intangible assets included $ 640 million of definite-lived Acquired marketed product rights ( </context> | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill |
) and $ 3.5 billion of indefinite-lived IPRD assets. The estimated fair value of both definite-lived Acquired marketed product rights and indefinite-lived IPRD assets was determined using an income approach valuation method. | text | 3.5 | monetaryItemType | text: <entity> 3.5 </entity> <entity type> monetaryItemType </entity type> <context> ) and $ 3.5 billion of indefinite-lived IPRD assets. The estimated fair value of both definite-lived Acquired marketed product rights and indefinite-lived IPRD assets was determined using an income approach valuation method. </context> | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill |
In 2023, BMS acquired the rights to Orum's ORM-6151 program, which is currently in Phase I clinical development. ORM-6151 is an anti-CD33 antibody-enabled GSPT1 degrader for the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndromes. The consideration included an upfront payment of $ 100 million, as well as contingent development milestone payments up to $ 80 million. The upfront payment was expensed to Acquired IPRD. | text | 80 | monetaryItemType | text: <entity> 80 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS acquired the rights to Orum's ORM-6151 program, which is currently in Phase I clinical development. ORM-6151 is an anti-CD33 antibody-enabled GSPT1 degrader for the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndromes. The consideration included an upfront payment of $ 100 million, as well as contingent development milestone payments up to $ 80 million. The upfront payment was expensed to Acquired IPRD. </context> | us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration |
In 2022, BMS acquired Turning Point for $ 4.1 billion of cash or $ 3.3 billion net of cash acquired. Turning Point was a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the common mutations and alterations that drive cancer growth. The acquisition provided BMS rights to Turning Point's lead asset, repotrectinib, and other clinical and pre-clinical stage assets. Repotrectinib was approved by the FDA in November 2023 and is marketed under the brand name | text | 4.1 | monetaryItemType | text: <entity> 4.1 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS acquired Turning Point for $ 4.1 billion of cash or $ 3.3 billion net of cash acquired. Turning Point was a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the common mutations and alterations that drive cancer growth. The acquisition provided BMS rights to Turning Point's lead asset, repotrectinib, and other clinical and pre-clinical stage assets. Repotrectinib was approved by the FDA in November 2023 and is marketed under the brand name </context> | us-gaap:PaymentsToAcquireBusinessesGross |
In 2022, BMS acquired Turning Point for $ 4.1 billion of cash or $ 3.3 billion net of cash acquired. Turning Point was a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the common mutations and alterations that drive cancer growth. The acquisition provided BMS rights to Turning Point's lead asset, repotrectinib, and other clinical and pre-clinical stage assets. Repotrectinib was approved by the FDA in November 2023 and is marketed under the brand name | text | 3.3 | monetaryItemType | text: <entity> 3.3 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS acquired Turning Point for $ 4.1 billion of cash or $ 3.3 billion net of cash acquired. Turning Point was a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the common mutations and alterations that drive cancer growth. The acquisition provided BMS rights to Turning Point's lead asset, repotrectinib, and other clinical and pre-clinical stage assets. Repotrectinib was approved by the FDA in November 2023 and is marketed under the brand name </context> | us-gaap:BusinessCombinationConsiderationTransferred1 |
(b) Includes pension settlement charges of $ 119 million in 2024 incurred in connection with the termination of the Bristol-Myers Squibb Puerto Rico, Inc. Retirement Income pension plan. | text | 119 | monetaryItemType | text: <entity> 119 </entity> <entity type> monetaryItemType </entity type> <context> (b) Includes pension settlement charges of $ 119 million in 2024 incurred in connection with the termination of the Bristol-Myers Squibb Puerto Rico, Inc. Retirement Income pension plan. </context> | us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1 |
As part of this agreement, BMS agreed to transfer 23.3 million of BeiGene ordinary shares of common stock held under a share subscription agreement back to BeiGene resulting in $ 322 million of expense that was included in Other (income)/expense, net in 2023. The expense was determined based on the closing price of the shares on the date of the transfer. | text | 322 | monetaryItemType | text: <entity> 322 </entity> <entity type> monetaryItemType </entity type> <context> As part of this agreement, BMS agreed to transfer 23.3 million of BeiGene ordinary shares of common stock held under a share subscription agreement back to BeiGene resulting in $ 322 million of expense that was included in Other (income)/expense, net in 2023. The expense was determined based on the closing price of the shares on the date of the transfer. </context> | us-gaap:LitigationSettlementExpense |
In July 2023, BMS entered into an agreement with AstraZeneca to settle all outstanding claims between the parties in the CTLA-4 litigation and the two PD-L1 antibody litigations. AstraZeneca is to pay an aggregate of $ 560 million to BMS in four payments through September 2026, which is subject to sharing arrangements with Ono and Dana-Farber. BMS's share was approximately $ 418 million, of which the net present value of $ 384 million was reflected in Other (income)/expense in 2023. | text | 560 | monetaryItemType | text: <entity> 560 </entity> <entity type> monetaryItemType </entity type> <context> In July 2023, BMS entered into an agreement with AstraZeneca to settle all outstanding claims between the parties in the CTLA-4 litigation and the two PD-L1 antibody litigations. AstraZeneca is to pay an aggregate of $ 560 million to BMS in four payments through September 2026, which is subject to sharing arrangements with Ono and Dana-Farber. BMS's share was approximately $ 418 million, of which the net present value of $ 384 million was reflected in Other (income)/expense in 2023. </context> | us-gaap:LitigationSettlementAmountAwardedFromOtherParty |
In July 2023, BMS entered into an agreement with AstraZeneca to settle all outstanding claims between the parties in the CTLA-4 litigation and the two PD-L1 antibody litigations. AstraZeneca is to pay an aggregate of $ 560 million to BMS in four payments through September 2026, which is subject to sharing arrangements with Ono and Dana-Farber. BMS's share was approximately $ 418 million, of which the net present value of $ 384 million was reflected in Other (income)/expense in 2023. | text | 418 | monetaryItemType | text: <entity> 418 </entity> <entity type> monetaryItemType </entity type> <context> In July 2023, BMS entered into an agreement with AstraZeneca to settle all outstanding claims between the parties in the CTLA-4 litigation and the two PD-L1 antibody litigations. AstraZeneca is to pay an aggregate of $ 560 million to BMS in four payments through September 2026, which is subject to sharing arrangements with Ono and Dana-Farber. BMS's share was approximately $ 418 million, of which the net present value of $ 384 million was reflected in Other (income)/expense in 2023. </context> | us-gaap:ProceedsFromLegalSettlements |
In July 2023, BMS entered into an agreement with AstraZeneca to settle all outstanding claims between the parties in the CTLA-4 litigation and the two PD-L1 antibody litigations. AstraZeneca is to pay an aggregate of $ 560 million to BMS in four payments through September 2026, which is subject to sharing arrangements with Ono and Dana-Farber. BMS's share was approximately $ 418 million, of which the net present value of $ 384 million was reflected in Other (income)/expense in 2023. | text | 384 | monetaryItemType | text: <entity> 384 </entity> <entity type> monetaryItemType </entity type> <context> In July 2023, BMS entered into an agreement with AstraZeneca to settle all outstanding claims between the parties in the CTLA-4 litigation and the two PD-L1 antibody litigations. AstraZeneca is to pay an aggregate of $ 560 million to BMS in four payments through September 2026, which is subject to sharing arrangements with Ono and Dana-Farber. BMS's share was approximately $ 418 million, of which the net present value of $ 384 million was reflected in Other (income)/expense in 2023. </context> | us-gaap:LitigationSettlementAmountAwardedFromOtherParty |
In 2022, BMS and Nimbus entered into a settlement resolving all legal claims and business interests pertaining to Nimbus' TYK2 inhibitor resulting in $ 40 million of income included in Other (income)/expense. The settlement also provides for BMS to receive additional amounts for contingent development, regulatory approval and sales-based milestones and 10 % of any change in control proceeds received by Nimbus related to its TYK2 inhibitor. In 2023, Takeda acquired 100 % ownership of Nimbus' TYK2 inhibitor for approximately $ 4.0 billion in upfront proceeds plus contingent sales-based milestones aggregating up to $ 2.0 billion. As a result, $ 400 million of income related to the change of control provision was included in Other (income)/expense in 2023. | text | 40 | monetaryItemType | text: <entity> 40 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS and Nimbus entered into a settlement resolving all legal claims and business interests pertaining to Nimbus' TYK2 inhibitor resulting in $ 40 million of income included in Other (income)/expense. The settlement also provides for BMS to receive additional amounts for contingent development, regulatory approval and sales-based milestones and 10 % of any change in control proceeds received by Nimbus related to its TYK2 inhibitor. In 2023, Takeda acquired 100 % ownership of Nimbus' TYK2 inhibitor for approximately $ 4.0 billion in upfront proceeds plus contingent sales-based milestones aggregating up to $ 2.0 billion. As a result, $ 400 million of income related to the change of control provision was included in Other (income)/expense in 2023. </context> | us-gaap:ProceedsFromLegalSettlements |
In 2022, BMS and Nimbus entered into a settlement resolving all legal claims and business interests pertaining to Nimbus' TYK2 inhibitor resulting in $ 40 million of income included in Other (income)/expense. The settlement also provides for BMS to receive additional amounts for contingent development, regulatory approval and sales-based milestones and 10 % of any change in control proceeds received by Nimbus related to its TYK2 inhibitor. In 2023, Takeda acquired 100 % ownership of Nimbus' TYK2 inhibitor for approximately $ 4.0 billion in upfront proceeds plus contingent sales-based milestones aggregating up to $ 2.0 billion. As a result, $ 400 million of income related to the change of control provision was included in Other (income)/expense in 2023. | text | 400 | monetaryItemType | text: <entity> 400 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS and Nimbus entered into a settlement resolving all legal claims and business interests pertaining to Nimbus' TYK2 inhibitor resulting in $ 40 million of income included in Other (income)/expense. The settlement also provides for BMS to receive additional amounts for contingent development, regulatory approval and sales-based milestones and 10 % of any change in control proceeds received by Nimbus related to its TYK2 inhibitor. In 2023, Takeda acquired 100 % ownership of Nimbus' TYK2 inhibitor for approximately $ 4.0 billion in upfront proceeds plus contingent sales-based milestones aggregating up to $ 2.0 billion. As a result, $ 400 million of income related to the change of control provision was included in Other (income)/expense in 2023. </context> | us-gaap:ProceedsFromLegalSettlements |
In 2023, BMS commenced a restructuring plan to accelerate the delivery of medicines to patients by evolving and streamlining its enterprise operating model in key areas, such as R&D, manufacturing, commercial and other functions, to ensure its operating model supports and is appropriately aligned with the Company’s strategy to invest in key priorities. These changes primarily include (i) transforming R&D operations to accelerate pipeline delivery, (ii) enhancing our commercial operating model, and (iii) establishing a more responsive manufacturing network. In 2025, BMS expanded the scope of activities supporting these key priorities. As a result, total charges for the 2023 Restructuring Plan are expected to be approximately $ 2.5 billion through 2027, with $ 1.0 billion incurred to date. The remaining charges consist primarily of employee termination costs and site exit costs, including impairment and accelerated depreciation of property, plant and equipment. | text | 2.5 | monetaryItemType | text: <entity> 2.5 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS commenced a restructuring plan to accelerate the delivery of medicines to patients by evolving and streamlining its enterprise operating model in key areas, such as R&D, manufacturing, commercial and other functions, to ensure its operating model supports and is appropriately aligned with the Company’s strategy to invest in key priorities. These changes primarily include (i) transforming R&D operations to accelerate pipeline delivery, (ii) enhancing our commercial operating model, and (iii) establishing a more responsive manufacturing network. In 2025, BMS expanded the scope of activities supporting these key priorities. As a result, total charges for the 2023 Restructuring Plan are expected to be approximately $ 2.5 billion through 2027, with $ 1.0 billion incurred to date. The remaining charges consist primarily of employee termination costs and site exit costs, including impairment and accelerated depreciation of property, plant and equipment. </context> | us-gaap:RestructuringAndRelatedCostExpectedCost1 |
In 2023, BMS commenced a restructuring plan to accelerate the delivery of medicines to patients by evolving and streamlining its enterprise operating model in key areas, such as R&D, manufacturing, commercial and other functions, to ensure its operating model supports and is appropriately aligned with the Company’s strategy to invest in key priorities. These changes primarily include (i) transforming R&D operations to accelerate pipeline delivery, (ii) enhancing our commercial operating model, and (iii) establishing a more responsive manufacturing network. In 2025, BMS expanded the scope of activities supporting these key priorities. As a result, total charges for the 2023 Restructuring Plan are expected to be approximately $ 2.5 billion through 2027, with $ 1.0 billion incurred to date. The remaining charges consist primarily of employee termination costs and site exit costs, including impairment and accelerated depreciation of property, plant and equipment. | text | 1.0 | monetaryItemType | text: <entity> 1.0 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS commenced a restructuring plan to accelerate the delivery of medicines to patients by evolving and streamlining its enterprise operating model in key areas, such as R&D, manufacturing, commercial and other functions, to ensure its operating model supports and is appropriately aligned with the Company’s strategy to invest in key priorities. These changes primarily include (i) transforming R&D operations to accelerate pipeline delivery, (ii) enhancing our commercial operating model, and (iii) establishing a more responsive manufacturing network. In 2025, BMS expanded the scope of activities supporting these key priorities. As a result, total charges for the 2023 Restructuring Plan are expected to be approximately $ 2.5 billion through 2027, with $ 1.0 billion incurred to date. The remaining charges consist primarily of employee termination costs and site exit costs, including impairment and accelerated depreciation of property, plant and equipment. </context> | us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 |
Restructuring and integration plans were initiated to realize expected cost synergies resulting from cost savings and avoidance from the acquisitions of Celgene (2019), Turning Point (2022), Mirati (2024), RayzeBio (2024) and Karuna (2024). For these plans, the remaining charges of approximately $ 250 million consist primarily of IT system integration costs, employee termination costs, and to a lesser extent, site exit costs, including impairment and accelerated depreciation of property, plant and equipment. | text | 250 | monetaryItemType | text: <entity> 250 </entity> <entity type> monetaryItemType </entity type> <context> Restructuring and integration plans were initiated to realize expected cost synergies resulting from cost savings and avoidance from the acquisitions of Celgene (2019), Turning Point (2022), Mirati (2024), RayzeBio (2024) and Karuna (2024). For these plans, the remaining charges of approximately $ 250 million consist primarily of IT system integration costs, employee termination costs, and to a lesser extent, site exit costs, including impairment and accelerated depreciation of property, plant and equipment. </context> | us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 |
Nondeductible R&D charges of $ 2.5 billion primarily relates to the impact of a $ 12.1 billion one-time, non-tax deductible charge for the acquisition of Karuna. | text | 2.5 | monetaryItemType | text: <entity> 2.5 </entity> <entity type> monetaryItemType </entity type> <context> Nondeductible R&D charges of $ 2.5 billion primarily relates to the impact of a $ 12.1 billion one-time, non-tax deductible charge for the acquisition of Karuna. </context> | us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment |
Nondeductible R&D charges of $ 2.5 billion primarily relates to the impact of a $ 12.1 billion one-time, non-tax deductible charge for the acquisition of Karuna. | text | 12.1 | monetaryItemType | text: <entity> 12.1 </entity> <entity type> monetaryItemType </entity type> <context> Nondeductible R&D charges of $ 2.5 billion primarily relates to the impact of a $ 12.1 billion one-time, non-tax deductible charge for the acquisition of Karuna. </context> | us-gaap:IncomeTaxReconciliationNondeductibleExpense |
U.S. Federal, state and foreign contingent tax matters include tax benefits related to lapse of statute and effectively settled contingent tax matters of $ 644 million in 2024 related to the resolution of Celgene's 2017-2019 IRS audit, $ 89 million in 2023 and $ 522 million in 2022. | text | 644 | monetaryItemType | text: <entity> 644 </entity> <entity type> monetaryItemType </entity type> <context> U.S. Federal, state and foreign contingent tax matters include tax benefits related to lapse of statute and effectively settled contingent tax matters of $ 644 million in 2024 related to the resolution of Celgene's 2017-2019 IRS audit, $ 89 million in 2023 and $ 522 million in 2022. </context> | us-gaap:IncomeTaxReconciliationTaxSettlements |
U.S. Federal, state and foreign contingent tax matters include tax benefits related to lapse of statute and effectively settled contingent tax matters of $ 644 million in 2024 related to the resolution of Celgene's 2017-2019 IRS audit, $ 89 million in 2023 and $ 522 million in 2022. | text | 89 | monetaryItemType | text: <entity> 89 </entity> <entity type> monetaryItemType </entity type> <context> U.S. Federal, state and foreign contingent tax matters include tax benefits related to lapse of statute and effectively settled contingent tax matters of $ 644 million in 2024 related to the resolution of Celgene's 2017-2019 IRS audit, $ 89 million in 2023 and $ 522 million in 2022. </context> | us-gaap:IncomeTaxReconciliationTaxSettlements |
U.S. Federal, state and foreign contingent tax matters include tax benefits related to lapse of statute and effectively settled contingent tax matters of $ 644 million in 2024 related to the resolution of Celgene's 2017-2019 IRS audit, $ 89 million in 2023 and $ 522 million in 2022. | text | 522 | monetaryItemType | text: <entity> 522 </entity> <entity type> monetaryItemType </entity type> <context> U.S. Federal, state and foreign contingent tax matters include tax benefits related to lapse of statute and effectively settled contingent tax matters of $ 644 million in 2024 related to the resolution of Celgene's 2017-2019 IRS audit, $ 89 million in 2023 and $ 522 million in 2022. </context> | us-gaap:IncomeTaxReconciliationTaxSettlements |
Puerto Rico imposed an excise tax on the gross company purchase price of goods sold from BMS’s manufacturer in Puerto Rico. The excise tax was recognized in Cost of products sold when the intra-entity sale occurred. For U.S. income tax purposes, the excise tax was not deductible but resulted in foreign tax credits that were generally recognized in BMS’s provision for income taxes when the excise tax was incurred. As of December 31, 2022, BMS amended its existing Puerto Rico decree, eliminating the excise tax and increasing its Puerto Rico tax rate to 10.5 % effective for the tax year beginning January 1, 2023, and extending BMS’s tax grants an additional 15 years to 2038. | text | 10.5 | percentItemType | text: <entity> 10.5 </entity> <entity type> percentItemType </entity type> <context> Puerto Rico imposed an excise tax on the gross company purchase price of goods sold from BMS’s manufacturer in Puerto Rico. The excise tax was recognized in Cost of products sold when the intra-entity sale occurred. For U.S. income tax purposes, the excise tax was not deductible but resulted in foreign tax credits that were generally recognized in BMS’s provision for income taxes when the excise tax was incurred. As of December 31, 2022, BMS amended its existing Puerto Rico decree, eliminating the excise tax and increasing its Puerto Rico tax rate to 10.5 % effective for the tax year beginning January 1, 2023, and extending BMS’s tax grants an additional 15 years to 2038. </context> | us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential |
The U.S. Federal net operating loss carryforwards were $ 2.0 billion at December 31, 2024. These carryforwards were acquired as a result of certain acquisitions and are subject to limitations under Section 382 of the Internal Revenue Code. The net operating loss carryforwards expire in varying amounts beginning in 2024. The foreign and state net operating loss carryforwards expire in varying amounts beginning in 2024 (certain amounts have unlimited lives). | text | 2.0 | monetaryItemType | text: <entity> 2.0 </entity> <entity type> monetaryItemType </entity type> <context> The U.S. Federal net operating loss carryforwards were $ 2.0 billion at December 31, 2024. These carryforwards were acquired as a result of certain acquisitions and are subject to limitations under Section 382 of the Internal Revenue Code. The net operating loss carryforwards expire in varying amounts beginning in 2024. The foreign and state net operating loss carryforwards expire in varying amounts beginning in 2024 (certain amounts have unlimited lives). </context> | us-gaap:OperatingLossCarryforwards |
At December 31, 2024, a valuation allowance of $ 929 million exists for the following items: $ 294 million primarily for foreign net operating loss and tax credit carryforwards, $ 453 million for state deferred tax assets including net operating loss and tax credit carryforwards and $ 182 million for U.S. Federal deferred tax assets including equity investment fair value adjustments and U.S. Federal net operating loss carryforwards. | text | 929 | monetaryItemType | text: <entity> 929 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024, a valuation allowance of $ 929 million exists for the following items: $ 294 million primarily for foreign net operating loss and tax credit carryforwards, $ 453 million for state deferred tax assets including net operating loss and tax credit carryforwards and $ 182 million for U.S. Federal deferred tax assets including equity investment fair value adjustments and U.S. Federal net operating loss carryforwards. </context> | us-gaap:DeferredTaxAssetsValuationAllowance |
At December 31, 2024, a valuation allowance of $ 929 million exists for the following items: $ 294 million primarily for foreign net operating loss and tax credit carryforwards, $ 453 million for state deferred tax assets including net operating loss and tax credit carryforwards and $ 182 million for U.S. Federal deferred tax assets including equity investment fair value adjustments and U.S. Federal net operating loss carryforwards. | text | 294 | monetaryItemType | text: <entity> 294 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024, a valuation allowance of $ 929 million exists for the following items: $ 294 million primarily for foreign net operating loss and tax credit carryforwards, $ 453 million for state deferred tax assets including net operating loss and tax credit carryforwards and $ 182 million for U.S. Federal deferred tax assets including equity investment fair value adjustments and U.S. Federal net operating loss carryforwards. </context> | us-gaap:DeferredTaxAssetsValuationAllowance |
At December 31, 2024, a valuation allowance of $ 929 million exists for the following items: $ 294 million primarily for foreign net operating loss and tax credit carryforwards, $ 453 million for state deferred tax assets including net operating loss and tax credit carryforwards and $ 182 million for U.S. Federal deferred tax assets including equity investment fair value adjustments and U.S. Federal net operating loss carryforwards. | text | 453 | monetaryItemType | text: <entity> 453 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024, a valuation allowance of $ 929 million exists for the following items: $ 294 million primarily for foreign net operating loss and tax credit carryforwards, $ 453 million for state deferred tax assets including net operating loss and tax credit carryforwards and $ 182 million for U.S. Federal deferred tax assets including equity investment fair value adjustments and U.S. Federal net operating loss carryforwards. </context> | us-gaap:DeferredTaxAssetsValuationAllowance |
At December 31, 2024, a valuation allowance of $ 929 million exists for the following items: $ 294 million primarily for foreign net operating loss and tax credit carryforwards, $ 453 million for state deferred tax assets including net operating loss and tax credit carryforwards and $ 182 million for U.S. Federal deferred tax assets including equity investment fair value adjustments and U.S. Federal net operating loss carryforwards. | text | 182 | monetaryItemType | text: <entity> 182 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024, a valuation allowance of $ 929 million exists for the following items: $ 294 million primarily for foreign net operating loss and tax credit carryforwards, $ 453 million for state deferred tax assets including net operating loss and tax credit carryforwards and $ 182 million for U.S. Federal deferred tax assets including equity investment fair value adjustments and U.S. Federal net operating loss carryforwards. </context> | us-gaap:DeferredTaxAssetsValuationAllowance |
Income tax payments were $ 3.9 billion in 2024, $ 4.3 billion in 2023 and $ 5.4 billion in 2022, including $ 799 million, $ 567 million and $ 339 million, respectively, for the transition tax following the TCJA enactment. The remaining amounts payable for the transition tax are $ 991 million in 2025 and $ 244 million in 2026. | text | 3.9 | monetaryItemType | text: <entity> 3.9 </entity> <entity type> monetaryItemType </entity type> <context> Income tax payments were $ 3.9 billion in 2024, $ 4.3 billion in 2023 and $ 5.4 billion in 2022, including $ 799 million, $ 567 million and $ 339 million, respectively, for the transition tax following the TCJA enactment. The remaining amounts payable for the transition tax are $ 991 million in 2025 and $ 244 million in 2026. </context> | us-gaap:IncomeTaxesPaidNet |
Income tax payments were $ 3.9 billion in 2024, $ 4.3 billion in 2023 and $ 5.4 billion in 2022, including $ 799 million, $ 567 million and $ 339 million, respectively, for the transition tax following the TCJA enactment. The remaining amounts payable for the transition tax are $ 991 million in 2025 and $ 244 million in 2026. | text | 4.3 | monetaryItemType | text: <entity> 4.3 </entity> <entity type> monetaryItemType </entity type> <context> Income tax payments were $ 3.9 billion in 2024, $ 4.3 billion in 2023 and $ 5.4 billion in 2022, including $ 799 million, $ 567 million and $ 339 million, respectively, for the transition tax following the TCJA enactment. The remaining amounts payable for the transition tax are $ 991 million in 2025 and $ 244 million in 2026. </context> | us-gaap:IncomeTaxesPaidNet |
Income tax payments were $ 3.9 billion in 2024, $ 4.3 billion in 2023 and $ 5.4 billion in 2022, including $ 799 million, $ 567 million and $ 339 million, respectively, for the transition tax following the TCJA enactment. The remaining amounts payable for the transition tax are $ 991 million in 2025 and $ 244 million in 2026. | text | 5.4 | monetaryItemType | text: <entity> 5.4 </entity> <entity type> monetaryItemType </entity type> <context> Income tax payments were $ 3.9 billion in 2024, $ 4.3 billion in 2023 and $ 5.4 billion in 2022, including $ 799 million, $ 567 million and $ 339 million, respectively, for the transition tax following the TCJA enactment. The remaining amounts payable for the transition tax are $ 991 million in 2025 and $ 244 million in 2026. </context> | us-gaap:IncomeTaxesPaidNet |
It is also reasonably possible that the total amount of unrecognized tax benefits at December 31, 2024 could decrease in the range of approximately $ 360 million to $ 400 million in the next twelve months as a result of the settlement of certain tax audits and other events. The expected change in unrecognized tax benefits may result in the payment of additional taxes, adjustment of certain deferred taxes and/or recognition of tax benefits. The following is a summary of major tax jurisdictions for which tax authorities may assert additional taxes based upon tax years currently under audit and subsequent years that are subject to audit: | text | 360 | monetaryItemType | text: <entity> 360 </entity> <entity type> monetaryItemType </entity type> <context> It is also reasonably possible that the total amount of unrecognized tax benefits at December 31, 2024 could decrease in the range of approximately $ 360 million to $ 400 million in the next twelve months as a result of the settlement of certain tax audits and other events. The expected change in unrecognized tax benefits may result in the payment of additional taxes, adjustment of certain deferred taxes and/or recognition of tax benefits. The following is a summary of major tax jurisdictions for which tax authorities may assert additional taxes based upon tax years currently under audit and subsequent years that are subject to audit: </context> | us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible |
It is also reasonably possible that the total amount of unrecognized tax benefits at December 31, 2024 could decrease in the range of approximately $ 360 million to $ 400 million in the next twelve months as a result of the settlement of certain tax audits and other events. The expected change in unrecognized tax benefits may result in the payment of additional taxes, adjustment of certain deferred taxes and/or recognition of tax benefits. The following is a summary of major tax jurisdictions for which tax authorities may assert additional taxes based upon tax years currently under audit and subsequent years that are subject to audit: | text | 400 | monetaryItemType | text: <entity> 400 </entity> <entity type> monetaryItemType </entity type> <context> It is also reasonably possible that the total amount of unrecognized tax benefits at December 31, 2024 could decrease in the range of approximately $ 360 million to $ 400 million in the next twelve months as a result of the settlement of certain tax audits and other events. The expected change in unrecognized tax benefits may result in the payment of additional taxes, adjustment of certain deferred taxes and/or recognition of tax benefits. The following is a summary of major tax jurisdictions for which tax authorities may assert additional taxes based upon tax years currently under audit and subsequent years that are subject to audit: </context> | us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible |
The total number of potential shares of common stock excluded from the diluted earnings per share computation because of the antidilutive impact was 38 million in 2024 and not material in 2023 and 2022. | text | 38 | sharesItemType | text: <entity> 38 </entity> <entity type> sharesItemType </entity type> <context> The total number of potential shares of common stock excluded from the diluted earnings per share computation because of the antidilutive impact was 38 million in 2024 and not material in 2023 and 2022. </context> | us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
Cumulative upwards adjustments and cumulative impairments and downward adjustments based on observable price changes in equity investments without RDFV still held as of December 31, 2024 were $ 220 million and $ 119 million, respectively. | text | 220 | monetaryItemType | text: <entity> 220 </entity> <entity type> monetaryItemType </entity type> <context> Cumulative upwards adjustments and cumulative impairments and downward adjustments based on observable price changes in equity investments without RDFV still held as of December 31, 2024 were $ 220 million and $ 119 million, respectively. </context> | us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount |
Cumulative upwards adjustments and cumulative impairments and downward adjustments based on observable price changes in equity investments without RDFV still held as of December 31, 2024 were $ 220 million and $ 119 million, respectively. | text | 119 | monetaryItemType | text: <entity> 119 </entity> <entity type> monetaryItemType </entity type> <context> Cumulative upwards adjustments and cumulative impairments and downward adjustments based on observable price changes in equity investments without RDFV still held as of December 31, 2024 were $ 220 million and $ 119 million, respectively. </context> | us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount |
into Cost of products sold for our foreign exchange contracts out of AOCL during the next 12 months. The notional amount of outstanding foreign currency exchange contracts was primarily $ 4.1 billion for the euro contracts and $ 1.2 billion for Japanese yen contracts as of December 31, 2024. | text | 4.1 | monetaryItemType | text: <entity> 4.1 </entity> <entity type> monetaryItemType </entity type> <context> into Cost of products sold for our foreign exchange contracts out of AOCL during the next 12 months. The notional amount of outstanding foreign currency exchange contracts was primarily $ 4.1 billion for the euro contracts and $ 1.2 billion for Japanese yen contracts as of December 31, 2024. </context> | us-gaap:DerivativeNotionalAmount |
into Cost of products sold for our foreign exchange contracts out of AOCL during the next 12 months. The notional amount of outstanding foreign currency exchange contracts was primarily $ 4.1 billion for the euro contracts and $ 1.2 billion for Japanese yen contracts as of December 31, 2024. | text | 1.2 | monetaryItemType | text: <entity> 1.2 </entity> <entity type> monetaryItemType </entity type> <context> into Cost of products sold for our foreign exchange contracts out of AOCL during the next 12 months. The notional amount of outstanding foreign currency exchange contracts was primarily $ 4.1 billion for the euro contracts and $ 1.2 billion for Japanese yen contracts as of December 31, 2024. </context> | us-gaap:DerivativeNotionalAmount |
BMS also enters into cross-currency swap contracts to hedge exposure to foreign currency exchange rate risk associated with its long-term debt denominated in euros. These contracts convert interest payments and principal repayment of the long-term debt to U.S. dollars from euros and are designated as cash flow hedges. The unrealized gains and losses on these contracts are reported in AOCL and reclassified to Other (income)/expense, net, in the same periods during which the hedged debt affects earnings. The notional amount of cross-currency swap contracts associated with long-term debt denominated in euros was $ 1.2 billion as of December 31, 2024. | text | 1.2 | monetaryItemType | text: <entity> 1.2 </entity> <entity type> monetaryItemType </entity type> <context> BMS also enters into cross-currency swap contracts to hedge exposure to foreign currency exchange rate risk associated with its long-term debt denominated in euros. These contracts convert interest payments and principal repayment of the long-term debt to U.S. dollars from euros and are designated as cash flow hedges. The unrealized gains and losses on these contracts are reported in AOCL and reclassified to Other (income)/expense, net, in the same periods during which the hedged debt affects earnings. The notional amount of cross-currency swap contracts associated with long-term debt denominated in euros was $ 1.2 billion as of December 31, 2024. </context> | us-gaap:DerivativeNotionalAmount |
In January 2024, BMS entered into forward interest rate contracts of a total notional value of $ 5.0 billion to hedge future interest rate risk associated with the 2024 Senior Unsecured Notes. The forward interest rate contracts were designated as cash flow hedges and terminated upon the issuance of the unsecured senior notes. The $ 131 million gain on the transaction was included in Other Comprehensive (Loss)/Income and is amortized as a reduction to interest expense over the term of the related debt. Amounts expected to be recognized during the subsequent 12 months on forward interest rate contracts are not material. | text | 5.0 | monetaryItemType | text: <entity> 5.0 </entity> <entity type> monetaryItemType </entity type> <context> In January 2024, BMS entered into forward interest rate contracts of a total notional value of $ 5.0 billion to hedge future interest rate risk associated with the 2024 Senior Unsecured Notes. The forward interest rate contracts were designated as cash flow hedges and terminated upon the issuance of the unsecured senior notes. The $ 131 million gain on the transaction was included in Other Comprehensive (Loss)/Income and is amortized as a reduction to interest expense over the term of the related debt. Amounts expected to be recognized during the subsequent 12 months on forward interest rate contracts are not material. </context> | us-gaap:DerivativeNotionalAmount |
In January 2024, BMS entered into forward interest rate contracts of a total notional value of $ 5.0 billion to hedge future interest rate risk associated with the 2024 Senior Unsecured Notes. The forward interest rate contracts were designated as cash flow hedges and terminated upon the issuance of the unsecured senior notes. The $ 131 million gain on the transaction was included in Other Comprehensive (Loss)/Income and is amortized as a reduction to interest expense over the term of the related debt. Amounts expected to be recognized during the subsequent 12 months on forward interest rate contracts are not material. | text | 131 | monetaryItemType | text: <entity> 131 </entity> <entity type> monetaryItemType </entity type> <context> In January 2024, BMS entered into forward interest rate contracts of a total notional value of $ 5.0 billion to hedge future interest rate risk associated with the 2024 Senior Unsecured Notes. The forward interest rate contracts were designated as cash flow hedges and terminated upon the issuance of the unsecured senior notes. The $ 131 million gain on the transaction was included in Other Comprehensive (Loss)/Income and is amortized as a reduction to interest expense over the term of the related debt. Amounts expected to be recognized during the subsequent 12 months on forward interest rate contracts are not material. </context> | us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax |
Cross-currency swap contracts and foreign currency forward contracts of $ 892 million as of December 31, 2024 are designated to hedge currency exposure of BMS's net investment in its foreign subsidiaries. Contract fair value changes are recorded in the foreign currency translation component of AOCL with a related offset in derivative asset or liability in the consolidated balance sheets. The notional amount of outstanding cross-currency swap and foreign currency forward contracts was primarily attributed to the Japanese yen of $ 498 million and euro of $ 345 million as of December 31, 2024. | text | 892 | monetaryItemType | text: <entity> 892 </entity> <entity type> monetaryItemType </entity type> <context> Cross-currency swap contracts and foreign currency forward contracts of $ 892 million as of December 31, 2024 are designated to hedge currency exposure of BMS's net investment in its foreign subsidiaries. Contract fair value changes are recorded in the foreign currency translation component of AOCL with a related offset in derivative asset or liability in the consolidated balance sheets. The notional amount of outstanding cross-currency swap and foreign currency forward contracts was primarily attributed to the Japanese yen of $ 498 million and euro of $ 345 million as of December 31, 2024. </context> | us-gaap:DerivativeNotionalAmount |
Cross-currency swap contracts and foreign currency forward contracts of $ 892 million as of December 31, 2024 are designated to hedge currency exposure of BMS's net investment in its foreign subsidiaries. Contract fair value changes are recorded in the foreign currency translation component of AOCL with a related offset in derivative asset or liability in the consolidated balance sheets. The notional amount of outstanding cross-currency swap and foreign currency forward contracts was primarily attributed to the Japanese yen of $ 498 million and euro of $ 345 million as of December 31, 2024. | text | 498 | monetaryItemType | text: <entity> 498 </entity> <entity type> monetaryItemType </entity type> <context> Cross-currency swap contracts and foreign currency forward contracts of $ 892 million as of December 31, 2024 are designated to hedge currency exposure of BMS's net investment in its foreign subsidiaries. Contract fair value changes are recorded in the foreign currency translation component of AOCL with a related offset in derivative asset or liability in the consolidated balance sheets. The notional amount of outstanding cross-currency swap and foreign currency forward contracts was primarily attributed to the Japanese yen of $ 498 million and euro of $ 345 million as of December 31, 2024. </context> | us-gaap:DerivativeNotionalAmount |
Cross-currency swap contracts and foreign currency forward contracts of $ 892 million as of December 31, 2024 are designated to hedge currency exposure of BMS's net investment in its foreign subsidiaries. Contract fair value changes are recorded in the foreign currency translation component of AOCL with a related offset in derivative asset or liability in the consolidated balance sheets. The notional amount of outstanding cross-currency swap and foreign currency forward contracts was primarily attributed to the Japanese yen of $ 498 million and euro of $ 345 million as of December 31, 2024. | text | 345 | monetaryItemType | text: <entity> 345 </entity> <entity type> monetaryItemType </entity type> <context> Cross-currency swap contracts and foreign currency forward contracts of $ 892 million as of December 31, 2024 are designated to hedge currency exposure of BMS's net investment in its foreign subsidiaries. Contract fair value changes are recorded in the foreign currency translation component of AOCL with a related offset in derivative asset or liability in the consolidated balance sheets. The notional amount of outstanding cross-currency swap and foreign currency forward contracts was primarily attributed to the Japanese yen of $ 498 million and euro of $ 345 million as of December 31, 2024. </context> | us-gaap:DerivativeNotionalAmount |
a) In 2023, the Company de-designated its remaining net investment hedge in debt denominated in euros of € 375 million, and the amount represents the effective portion of foreign exchange loss on the remeasurement of the debt. | text | 375 | monetaryItemType | text: <entity> 375 </entity> <entity type> monetaryItemType </entity type> <context> a) In 2023, the Company de-designated its remaining net investment hedge in debt denominated in euros of € 375 million, and the amount represents the effective portion of foreign exchange loss on the remeasurement of the debt. </context> | us-gaap:DebtInstrumentFaceAmount |
As of December 31, 2024, under the commercial paper program, BMS could issue up to $ 7.0 billion of unsecured notes, with maturities of not more than 365 days from the date of issuance. Of this amount, $ 3.0 billion was issued and repaid during the year ended December 31, 2024. In January 2025, the maximum amount of commercial paper that could be issued was reduced to $ 5.0 billion. | text | 3.0 | monetaryItemType | text: <entity> 3.0 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, under the commercial paper program, BMS could issue up to $ 7.0 billion of unsecured notes, with maturities of not more than 365 days from the date of issuance. Of this amount, $ 3.0 billion was issued and repaid during the year ended December 31, 2024. In January 2025, the maximum amount of commercial paper that could be issued was reduced to $ 5.0 billion. </context> | us-gaap:ProceedsFromIssuanceOfCommercialPaper |
(a) As of December 31, 2024, floating rate equals SOFR+ 0.49 %. | text | 0.49 | percentItemType | text: <entity> 0.49 </entity> <entity type> percentItemType </entity type> <context> (a) As of December 31, 2024, floating rate equals SOFR+ 0.49 %. </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
The fair value of Long-term debt, including the current portion, was $ 45.3 billion and $ 36.7 billion as of December 31, 2024 and 2023, respectively, valued using Level 2 inputs which are based upon the quoted market prices for the same or similar debt instruments. The fair value of Short-term debt obligations approximates the carrying value due to the short maturities of the debt instruments. | text | 45.3 | monetaryItemType | text: <entity> 45.3 </entity> <entity type> monetaryItemType </entity type> <context> The fair value of Long-term debt, including the current portion, was $ 45.3 billion and $ 36.7 billion as of December 31, 2024 and 2023, respectively, valued using Level 2 inputs which are based upon the quoted market prices for the same or similar debt instruments. The fair value of Short-term debt obligations approximates the carrying value due to the short maturities of the debt instruments. </context> | us-gaap:DebtInstrumentFairValue |
The fair value of Long-term debt, including the current portion, was $ 45.3 billion and $ 36.7 billion as of December 31, 2024 and 2023, respectively, valued using Level 2 inputs which are based upon the quoted market prices for the same or similar debt instruments. The fair value of Short-term debt obligations approximates the carrying value due to the short maturities of the debt instruments. | text | 36.7 | monetaryItemType | text: <entity> 36.7 </entity> <entity type> monetaryItemType </entity type> <context> The fair value of Long-term debt, including the current portion, was $ 45.3 billion and $ 36.7 billion as of December 31, 2024 and 2023, respectively, valued using Level 2 inputs which are based upon the quoted market prices for the same or similar debt instruments. The fair value of Short-term debt obligations approximates the carrying value due to the short maturities of the debt instruments. </context> | us-gaap:DebtInstrumentFairValue |
In 2024, BMS issued an aggregate principal amount of $ 13.0 billion of unsecured senior notes ("2024 Senior Unsecured Notes"), with proceeds, net of discount and loan issuance costs, of $ 12.9 billion, consisting of: | text | 13.0 | monetaryItemType | text: <entity> 13.0 </entity> <entity type> monetaryItemType </entity type> <context> In 2024, BMS issued an aggregate principal amount of $ 13.0 billion of unsecured senior notes ("2024 Senior Unsecured Notes"), with proceeds, net of discount and loan issuance costs, of $ 12.9 billion, consisting of: </context> | us-gaap:DebtInstrumentFaceAmount |
In 2024, BMS issued an aggregate principal amount of $ 13.0 billion of unsecured senior notes ("2024 Senior Unsecured Notes"), with proceeds, net of discount and loan issuance costs, of $ 12.9 billion, consisting of: | text | 12.9 | monetaryItemType | text: <entity> 12.9 </entity> <entity type> monetaryItemType </entity type> <context> In 2024, BMS issued an aggregate principal amount of $ 13.0 billion of unsecured senior notes ("2024 Senior Unsecured Notes"), with proceeds, net of discount and loan issuance costs, of $ 12.9 billion, consisting of: </context> | us-gaap:DeferredFinanceCostsNet |
The Company used the net proceeds from this offering to partially fund the acquisitions of RayzeBio and Karuna (see "—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements" for further information) and used the remaining net proceeds for general corporate purposes. In connection with the issuance of the 2024 Senior Unsecured Notes, the Company terminated the $ 10.0 billion 364-day senior unsecured delayed draw term loan facility, which was entered into in February 2024 to provide bridge financing for the RayzeBio and Karuna acquisitions. | text | 10.0 | monetaryItemType | text: <entity> 10.0 </entity> <entity type> monetaryItemType </entity type> <context> The Company used the net proceeds from this offering to partially fund the acquisitions of RayzeBio and Karuna (see "—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements" for further information) and used the remaining net proceeds for general corporate purposes. In connection with the issuance of the 2024 Senior Unsecured Notes, the Company terminated the $ 10.0 billion 364-day senior unsecured delayed draw term loan facility, which was entered into in February 2024 to provide bridge financing for the RayzeBio and Karuna acquisitions. </context> | us-gaap:DebtInstrumentFaceAmount |
In 2023, BMS issued an aggregate principal amount of $ 4.5 billion of fixed rate unsecured senior notes. The Company used the net proceeds of the offering to finance the acquisition of Mirati in January 2024 and for other general corporate purposes. In 2022, BMS issued an aggregate principal amount of $ 6.0 billion of fixed rate unsecured senior notes with net proceeds of $ 5.9 billion. | text | 4.5 | monetaryItemType | text: <entity> 4.5 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS issued an aggregate principal amount of $ 4.5 billion of fixed rate unsecured senior notes. The Company used the net proceeds of the offering to finance the acquisition of Mirati in January 2024 and for other general corporate purposes. In 2022, BMS issued an aggregate principal amount of $ 6.0 billion of fixed rate unsecured senior notes with net proceeds of $ 5.9 billion. </context> | us-gaap:DebtInstrumentCarryingAmount |
In 2023, BMS issued an aggregate principal amount of $ 4.5 billion of fixed rate unsecured senior notes. The Company used the net proceeds of the offering to finance the acquisition of Mirati in January 2024 and for other general corporate purposes. In 2022, BMS issued an aggregate principal amount of $ 6.0 billion of fixed rate unsecured senior notes with net proceeds of $ 5.9 billion. | text | 6.0 | monetaryItemType | text: <entity> 6.0 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS issued an aggregate principal amount of $ 4.5 billion of fixed rate unsecured senior notes. The Company used the net proceeds of the offering to finance the acquisition of Mirati in January 2024 and for other general corporate purposes. In 2022, BMS issued an aggregate principal amount of $ 6.0 billion of fixed rate unsecured senior notes with net proceeds of $ 5.9 billion. </context> | us-gaap:DebtInstrumentCarryingAmount |
In 2023, BMS issued an aggregate principal amount of $ 4.5 billion of fixed rate unsecured senior notes. The Company used the net proceeds of the offering to finance the acquisition of Mirati in January 2024 and for other general corporate purposes. In 2022, BMS issued an aggregate principal amount of $ 6.0 billion of fixed rate unsecured senior notes with net proceeds of $ 5.9 billion. | text | 5.9 | monetaryItemType | text: <entity> 5.9 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS issued an aggregate principal amount of $ 4.5 billion of fixed rate unsecured senior notes. The Company used the net proceeds of the offering to finance the acquisition of Mirati in January 2024 and for other general corporate purposes. In 2022, BMS issued an aggregate principal amount of $ 6.0 billion of fixed rate unsecured senior notes with net proceeds of $ 5.9 billion. </context> | us-gaap:ProceedsFromDebtNetOfIssuanceCosts |
In 2022, BMS purchased aggregate principal amount of $ 6.0 billion of certain of its debt securities for $ 6.6 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $ 266 million loss on debt redemption was recognized based on the carrying value of the debt and included in Other (income)/expense, net. | text | 6.0 | monetaryItemType | text: <entity> 6.0 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS purchased aggregate principal amount of $ 6.0 billion of certain of its debt securities for $ 6.6 billion of cash in a series of tender offers and “make whole” redemptions. In connection with these transactions, a $ 266 million loss on debt redemption was recognized based on the carrying value of the debt and included in Other (income)/expense, net. </context> | us-gaap:ExtinguishmentOfDebtAmount |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.